Immix Biopharma (NASDAQ:IMMX) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Immix Biopharma (NASDAQ:IMMX) from a hold rating to a sell rating in a report published on Saturday morning.

IMMX has been the subject of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research note on Wednesday, October 8th. HC Wainwright lifted their price objective on Immix Biopharma from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, September 12th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Immix Biopharma currently has a consensus rating of “Hold” and an average target price of $8.00.

Immix Biopharma Stock Down 8.8%

Shares of IMMX opened at $4.44 on Friday. The company has a market cap of $149.10 million, a P/E ratio of -5.77 and a beta of 0.31. Immix Biopharma has a fifty-two week low of $1.34 and a fifty-two week high of $7.73. The firm’s 50 day moving average price is $4.87 and its 200 day moving average price is $3.35.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings results on Friday, November 7th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Research analysts forecast that Immix Biopharma will post -0.87 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IMMX. Tritonpoint Wealth LLC purchased a new stake in Immix Biopharma during the second quarter worth approximately $51,000. Velan Capital Investment Management LP acquired a new stake in Immix Biopharma during the second quarter worth approximately $52,000. Tocqueville Asset Management L.P. raised its holdings in Immix Biopharma by 37.4% during the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after purchasing an additional 10,950 shares in the last quarter. Imprint Wealth LLC purchased a new stake in shares of Immix Biopharma during the 3rd quarter worth approximately $141,000. Finally, United Capital Financial Advisors LLC acquired a new position in shares of Immix Biopharma in the 3rd quarter valued at $148,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.